Mouse study suggests endocannabinoid receptors help mediate anti-inflammatory effects in colitis

When researchers administered CB1 or CB2 receptor antagonists before treating colitis-induced mice with McN-A-343 (a muscarinic receptor agonist), the drug's anti-inflammatory benefits were significantly reversed, with increased intestinal damage, pro-inflammatory cytokines, oxidative stress, and NF-kB expression.

Male mice received acetic acid-induced colitis, then were treated with the M1 muscarinic receptor agonist McN-A-343. CB1 antagonist AM251 and CB2 antagonist AM630 were given 30 minutes before treatment. After 18 hours, colon tissue was analyzed for macroscopic and microscopic damage, inflammatory markers, oxidative stress, and protein expression via Western blot.

Ulcerative colitis affects millions worldwide and current treatments have significant limitations. This study reveals crosstalk between the cholinergic and endocannabinoid systems in gut inflammation, opening a potential new pathway for therapeutic development.

The finding that cannabinoid receptors are required for the anti-inflammatory action of a non-cannabinoid drug reveals that the endocannabinoid system may be a more central player in gut inflammation pathways than previously appreciated. This crosstalk could inform combination therapy approaches.

This is a mouse model using chemically induced colitis, which does not fully replicate human ulcerative colitis. Only male mice were used. The acute 18-hour timeframe does not reflect chronic disease. Dexamethasone was the only comparator.